Alumis Inc. (NASDAQ:ALMS – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $40.30.
ALMS has been the topic of a number of recent analyst reports. Wall Street Zen raised Alumis from a “strong sell” rating to a “hold” rating in a research report on Sunday. Guggenheim lifted their target price on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Citigroup restated a “neutral” rating on shares of Alumis in a report on Monday, August 17th. Wells Fargo & Company increased their target price on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $39.00 target price on shares of Alumis in a research report on Friday, May 15th.
Check Out Our Latest Stock Report on ALMS
Alumis Stock Performance
Alumis (NASDAQ:ALMS – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The business had revenue of $1.66 million during the quarter, compared to analyst estimates of $3.65 million. Equities research analysts predict that Alumis will post -2.95 earnings per share for the current year.
Insiders Place Their Bets
In other Alumis news, insider Jorn Drappa sold 2,447 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $64,527.39. Following the completion of the transaction, the insider owned 56,892 shares of the company’s stock, valued at $1,500,242.04. The trade was a 4.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David M. Goldstein sold 2,596 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $68,456.52. Following the sale, the insider owned 30,970 shares of the company’s stock, valued at $816,678.90. This trade represents a 7.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 19,953 shares of company stock valued at $534,311 in the last three months. Company insiders own 33.70% of the company’s stock.
Hedge Funds Weigh In On Alumis
A number of institutional investors have recently made changes to their positions in ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after purchasing an additional 4,926 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Alumis by 24.0% during the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock worth $378,000 after buying an additional 11,949 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Alumis during the first quarter worth approximately $111,000. Rhumbline Advisers boosted its position in shares of Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after acquiring an additional 2,949 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Alumis by 163.2% in the second quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock valued at $3,504,000 after acquiring an additional 724,133 shares during the period.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
- Five stocks we like better than Alumis
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
